See Policy CPT/HCPCS CODE section below for any prior authorization requirements

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

All lines of business except Medicare

**BENEFIT APPLICATION**

Medicaid Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**POLICY CRITERIA**

*Thermal Intradiscal Procedures*

I. The use of thermal intradiscal procedures are considered **investigational and are not covered** for the treatment of low back pain, including but not limited to, the following (A.-F.):

   A. Intradiscal Biacuplasty (IDB)
   B. Intradiscal electrothermal therapy (IDET), also known as intradiscal thermal annuloplasty (IDTA)
   C. Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)
D. Percutaneous (or plasma) disc compression (PDD) or coblation
E. Radiofrequency annuloplasty (RA)
F. Targeted disc decompression (TDD)

Non-Thermal Intradiscal Procedures

II. Non-thermal intradiscal procedures are considered investigational and are not covered for the treatment of low back pain, including but not limited to, the following (A.-B.):

A. Glucocorticoid intradiscal injections
B. Methylene blue intradiscal injections

BILLING GUIDELINES

All intradiscal procedures are performed with radiologic or fluoroscopic guidance. Therefore, radiologic or fluoroscopic guidance is also considered not covered as an ancillary service when performed in conjunction with intradiscal procedures.

Non-thermal intradiscal injections should not be billed with the following codes:

- 20610: Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance.
- 20611: Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting.
- 62281: Injection/infusion of neurolytic substance (eg, alcohol, phenol, iced saline solutions), with or without other therapeutic substance; epidural, cervical or thoracic.

CPT/HCPCS CODES

<table>
<thead>
<tr>
<th>All Lines of Business Except Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Not Covered</strong></td>
</tr>
<tr>
<td>22526</td>
</tr>
<tr>
<td>22527</td>
</tr>
</tbody>
</table>
Unlisted Codes
All unlisted codes will be reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is billed related to services addressed in this policy then it will be denied as not covered.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22899</td>
<td>Unlisted procedure, spine</td>
</tr>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

DESCRIPTION

Background

Per a 2010 Hayes review¹:

“Low back pain is a major cause of disability in adults, occurring in 15% to 20% of the working-age population annually and 80% of adults at some point in their lives. While most occurrences of low back pain resolve without intervention, approximately 10% of the cases do not respond to conservative treatment and are associated with chronic and disabling pain. The most prevalent cause of low back pain is intervertebral disc disease (IDD). Intervertebral discs consist of an outer component known as the annulus fibrosus, and an inner component known as the nucleus pulposus. IDD results in discogenic pain, which is persistent and disabling. When involving discs of the lower back, the resulting pain is characterized by chronic and disabling pain in the low back, may involve lesser pain in the groin or legs, and typically worsens with sitting or standing and subsides with lying down.”¹

Treatments

Thermal Intradiscal Procedures

Initial treatment for discogenic low back pain entails conservative measures including pain medications, physical exercises, physical therapy (PT), back brace, intradiscal corticosteroid injections, and/or nerve blocks.

Surgical treatment is offered only if the pain is not responsive to conservative measures. Surgical procedures include disc excision, spinal fusion (arthroplasty), or total artificial disc replacement.

Percutaneous thermal intradiscal treatments, also known as thermal intradiscal procedures (TIPs), are proposed as minimally invasive alternatives to invasive surgical procedures.

Per the Centers for Medicare & Medicaid (CMS) NCD regarding thermal intradiscal procedures:²
“Thermal intradiscal procedures involve the insertion of a catheter(s)/probe(s) into the spinal disc under fluoroscopic guidance in order to produce, or apply, heat and/or disruption within the disc to relieve low back pain.”

This includes percutaneous intradiscal techniques that employ the use of a radiofrequency energy source or electrothermal energy to apply or create heat and/or disruption within the disc for coagulation and/or decompression of disc material to treat symptomatic patients with annular disruption of a contained herniated disc, to seal annular tears or fissures, or destroy nociceptors for the purpose of relieving pain. This includes techniques that use single or multiple probe(s)/catheter(s), which utilize a resistance coil or other delivery system technology, are flexible or rigid, and are placed within the nucleus, the nuclear-annular junction, or the annulus.

TIPs procedures performed within the annulus include intradiscal electrothermal therapy (IDET), intradiscal radiofrequency thermocoagulation (IRFT), intradiscal biaucuplasty (IDB), and radiofrequency annuloplasty (RA). Procedures performed within the nucleus of the disc include percutaneous (or plasma) disc decompression (PDD) or ablation, and targeted disc decompression (TDD) procedures.

At times thermal intradiscal procedures are identified, or labeled, based on the name of the catheter(s)/probe(s) that are used (e.g., SpineCath, DiscTRODE, Spine Wand, Accutherm, or TransDiscal electrodes); and each technique or device has its own protocol for application of therapy.”

**Non-Thermal Intradiscal Procedures**

Non-thermal intradiscal procedures can include various combinations of injectable medications and substances such as steroids, normal saline, and anesthetics that may alleviate discogenic pain. Both steroids and non-steroidal anti-inflammatory drugs have been shown partially effective in treating pain due to inflammation. As a result, it is purported that intradiscal injections may improve pain by contracting tissues surrounding the disc and promoting spinal segment stabilization. Recent studies primarily evaluate the efficacy of glucocorticoid and methylene blue intradiscal injections.

**REVIEW OF EVIDENCE**

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of thermal and non-thermal intradiscal procedures for the treatment of low back pain. Below is a summary of the available evidence identified through March 2020. Due to the volume of literature, the evidence review on the various procedures is focused on systematic reviews.

**Thermal Intradiscal Procedures**

Systematic reviews have been published on the following percutaneous thermal intradiscal procedures:
• Intradiscal biacuplasty (IDB)\(^4\text{-}7\)
• Intradiscal electrothermal therapy (IDET), also known as Intradiscal thermal annuloplasty (IDTA)\(^1\text{-}4\text{-}13\)
• Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)\(^7\text{-}12\)
• Percutaneous (or plasma) disc compression (PDD) or coblation\(^14\text{-}17\)
• Radiofrequency annuloplasty (RA)\(^4\text{-}6\)
• Targeted disc decompression (TDD)\(^17\)

Many of the systematic reviews suffered from one or more of the following limitations:

- Heterogeneous in the methods used to examine primary studies evaluating various percutaneous thermal intradiscal procedures:
  - included or focused entirely on nonrandomized studies due to a paucity of published randomized controlled trials (RCTs)
  - included a large number of retrospective studies
  - included studies with heterogeneous patient cohorts (e.g. low back pain due to various etiologies)
  - reviews that did include RCTs reported that study criteria used in these RCTs were inconsistent (specifically regarding inclusion/exclusion criteria on age, body mass index, duration of symptoms)
- Two of the reviews were industry sponsored.\(^8\text{-}9\)

All reviews mentioned the need for larger, better-quality studies with longer-term follow-up. The majority of recent reviews were unable to draw definitive conclusions regarding the efficacy of any one procedure as a treatment for low back pain. Many of the reviews indicated that ideal patient selection for each procedure remains to be determined.

Overall, the body of evidence for any given procedure suffers from one or more of the following limitations:

- extremely limited number of randomized controlled trials (RCTs) reporting outcomes for any given procedure
- primary studies, including very small numbers of RCTS, were of low- to very-low quality of due to methodological limitations including:
  - small sample size (under 100 patients)
  - insufficient statistical power
  - lack of blinding
  - primary outcomes reported consisted mostly of subjective, patient-reported outcomes
- inadequate follow-up
- heterogeneity of:
  - comparator treatment
  - primary outcomes reported
- conflicting or no evidence of short-term or long-term reductions in pain and/or disability.
Non-Thermal Intradiscal Procedures

No systematic reviews have been published within the last five years examining the efficacy of the following non-thermal intradiscal therapies for the treatment of low back pain:

- Glucocorticoid intradiscal injections
- Methylene Blue intradiscal injections

Glucocorticoid Intradiscal Injections

In 2017, Nguyen and colleagues conducted a RCT evaluating the efficacy of a single glucocorticoid intradiscal injection (GC-IDI) for the treatment of chronic lower back pain (LBP) and active discopathy. In total, 135 patients received a single GC-IDI during discography (n=67) or discography alone (n=68). The primary outcome of interest was the percentage of patients with LBP intensity rating less than 40 on a scale of 0 (no pain) to 100 (maximum pain) in ten point increments over the past 48 hours and 1 month. Secondary outcomes were LBP intensity at 12 months, spine-specific limitations in activities, health-related QOL (HRQL), anxiety and depression, employment status, and use of analgesics and non-steroidal anti-inflammatory drugs at 1 and 12 month follow-up periods. At one month follow-up, GC-IDI patients responded better than the control group. At 1 month after the intervention, the percentage of responders (LBP intensity less than 40) was higher in the GC-IDI group (36 of 65 [55.4 %]) than the control group (21 of 63 [33.3 %]) (ARD: 22.1 percentage points [95 % CI: 5.5 to 38.7 percentage points]; \( p = 0.009 \)). However, groups did not differ in LBP intensity at 12 months and in most secondary outcomes at either 1 or 12 months. Authors concluded that a single GC-IDI reduced LBP at 1 month but not at 12 months.18

Methylene Blue Intradiscal Injections

Two meta-analyses were published on methylene blue for back pain. Guo et al. reviewed non-randomized data from 5 studies on discogenic low back pain. A pooled analysis found that visual analog and numerical rating scale pain scores and disability scores were lowered among participants, but there were no comparison groups and therefore no conclusions can be drawn from the results. In the second meta-analysis, Yao et al reviewed 3 RCTS on general back pain and found that, compared to a control group, pain scores were reduced at 24-48 hours (standard mean difference: -1.69; 95% CI: -2.07 to -1.32; \( p< 0.001 \)) and at 2-3 months (mean difference: -1.09; 95% CI: -1.62 to -0.56; \( p< 0.0001 \)), but not at 6 months. All studies from both meta-analyses suffered from high levels of biases. Sample sizes were small, ranging from 8-52 participants. There was high heterogeneity in participant populations, outcome measures, and results. Both meta-analyses are of poor quality and do not offer substantial evidence for the use of methylene blue intradiscal injections for back pain.
MEDICAL POLICY

Back: Intradiscal Procedures for Low Back Pain
(All Lines of Business Except Medicare)

Two recent non-randomized trials\textsuperscript{21,22} examined the efficacy of methylene blue for the treatment of low back pain. Despite reporting statistically significant improvements, both studies suffered from small sample sizes (n=15-33), inadequate follow-up (6-12 months) and a lack of comparator groups.

CLINICAL PRACTICE GUIDELINES

Thermal Intradiscal Procedures

National Institute for Health and Care Excellence (NICE)

In 2016, NICE published interventional procedural guidance (IPG) documents for a number of percutaneous thermal intradiscal procedures. NICE indicated that the following procedures, “should only be used with special arrangements for clinical governance, consent and audit or research.”

- Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica (IPG544).\textsuperscript{23,24}
  - NICE stated that “the evidence on efficacy is inconsistent and of poor quality.”
- Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (IPG545).\textsuperscript{24}
  - NICE stated that “the evidence on its efficacy is limited in quantity and quality.”\textsuperscript{25}

NICE also indicated that the evidence on efficacy of percutaneous coblation of the intervertebral disc for low back pain and sciatica was “adequate”. (IPG543). However, this guidance was based on one systematic review that included three key studies (two RCTs and one large case series).

American Society of Interventional Pain Physicians (ASIPP)

In 2013, the ASIPP reaffirmed their guideline regarding interventional techniques for the treatment of chronic spinal pain.\textsuperscript{26} ASIPP made the following statements regarding thermal annular procedures:

- “The evidence supporting the efficacy of IDET is limited to fair.” (Based on evidence of two randomized trials and five observational studies.)
- “There is limited to fair evidence for the effectiveness of biacuplasty for treating low back pain, based on one randomized trial with modest results.”
- “The evidence for various modes of percutaneous disc decompression (PDD) is limited to fair for nucleoplasty.” (Based on one RCT and 15 observational studies.)
Non-Thermal Intradiscal Procedures

*National Institute for Health and Care Excellence (NICE)*

In 2016, NICE published a guideline for the assessment and management of low back pain and sciatica in patients over 16 years old. The guideline recommended against the use of spinal injections for managing low back pain.27

**POLICY SUMMARY**

There is insufficient evidence that the use of percutaneous thermal and non-thermal intradiscal procedures are safe and effective compared to standard of care (surgical and non-surgical) treatments for low back pain. Overall, there is a paucity of well-designed randomized controlled trials with adequate power and follow-up. In addition, no evidence-based clinical practice guidelines were identified that strongly support the use of these procedures.

**INSTRUCTIONS FOR USE**

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

**REGULATORY STATUS**

*U.S. Food & Drug Administration (FDA)*

There are a number of radiofrequency (RF) coagulation devices that have been cleared for marketing by the FDA through the 510(k) clearance process that may be used for disc nucleotomy. Examples of these devices include:

- Nucleotomy Catheter (Oratec Interventions, Inc.)
- SpineCATH™ Intradiscal Catheter (Oratec Interventions, Inc.)
- Radionics RF Disc Catheter Electrode System (Radionics Inc.)
- TransDiscal ™ System (Baylis Medical) for biacuplasty
• Spine Wand (ArthroCare, Corporation)

Note: Some of the devices listed above are no longer available, but were identified during the evidence review.

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

REFERENCES


